The Hepatitis Insulin Center (HIC) was established in November 2014, is the first embodied integrated medical center for hepatitis and pancreatic cancer in Asia, and is a national standard clinical demonstration base for primary liver cancer, the accreditation unit of the Chinese Research Hospital Association for the Accreditation of the National Academy of Hepatitis Surgery. The center is composed of related sub-disciplines such as hepatochology, hepatocholaic pancreatology, liver transplantation, hepatocholaic oncology comprehensive diagnosis, hepatocholaic intervention therapy, pediatric hepatitis diagnosis, hepatocholaic severity monitoring room, and other relevant sub-disciplines to provide precise medical and multidisciplinary diagnostic models for patients with hepatocholaic disease (see one-stop services), systematic diagnosis and complete process management.
No data yet
No data yet